Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal ...

Sumatriptan 5mg, 20mg; per spray. The vascular 5-HT 1 receptor subtype to which sumatriptan binds selectively, and through which it presumably exerts its antimigrainous effect, is present on cranial ...

Imitrex (sumatriptan) was the first migraine medication approved to abort an attack. Discover its side effects, benefits, and ...

MAPLE GROVE, Minn., Oct. 2, 2019 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Tosymra ™ (sumatriptan) Nasal Spray, 10 mg for the acute treatment of ...

Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...

MUMBAI, India, March 2, 2021 /CNW/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug ...

Tosymra (sumatriptan) is a prescription drug used to treat migraine. The drug comes as a nasal spray. You usually use a single dose, which may be repeated two more times in a 24-hour period if needed.

DUBLIN--(BUSINESS WIRE)--The "Inhalation and Nasal Spray Generic Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Inhalation and ...

Tosymra (sumatriptan) is a brand-name drug that’s prescribed to treat migraine with or without aura in adults. Tosymra comes as a nasal spray that’s used when needed to manage a migraine episode.